The company announced it filed its submission to prevent COVID-19 in individuals 18 years of age and older.
Moderna announced it has submitted its formal Biologics License Application (BLA) with the Food and Drug Administration (FDA) for its COVID-19 Vaccine, mRNA-1273.
“This BLA submission for our COVID-19 vaccine, which we began in June, is an important milestone in our battle against COVID-19 and for Moderna, as this is the first BLA submission in our company’s history,” Moderna CEO Stéphane Bancel, said. “We are pleased that our COVID-19 vaccine is showing durable efficacy of 93% through 6 months after dose 2.
The filing come from data collected in the company’s phase 3 COVE study. Peer-reviewed data from the COVE Study Group confirmed that mRNA-1273 has shown 93% efficacy in COVID-19 among adult trial participants at high risk for SARS-CoV-2 infection or its complications.
The COVE Study Group reported results from the randomized, observer-blind, placebo-controlled trial underway in 99 centers throughout the US. The study included 30,420 volunteers who had been randomly enrolled 1:1 to either intramuscular two-dose 100mcg vaccine or placebo (n = 15,210 each)
Full licensure of the vaccine for active immunization to prevent COVID-19 in individuals 18 years of age and older.
The FDA has not set a timeline yet for review of the Moderna vaccine.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.